Immunotherapy and Personalized Treatments
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Immunotherapy and Personalized Treatments
-
Lu par :
-
De :
So far, immunotherapy has been a game-changer in other cancers but not pancreatic cancer. Is that finally changing?
In this episode of PancChat, host Alisyn Camerota sits down with Dr. Elizabeth Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and chief medical advisor of the Lustgarten Foundation. Dr. Jaffee breaks down the science behind pancreatic cancer's resistance to immunotherapy, the promise of cancer vaccines, and the emergence of KRAS inhibitors as a new class of targeted therapies. After thirty years in the field, she shares why she is more optimistic than ever.
PancChat is a collaboration between Let's Win Pancreatic Cancer and PanCAN.
adbl_web_anon_alc_button_suppression_c
Aucun commentaire pour le moment